Mice that are part of the Collaborative Cross project at Oak Ridge National Laboratory are helping scientists around the world learn more about possible causes of drug abuse, diabetes, sleep disorders, stress and pain, kidney disease and a number of other conditions that affect millions of people.
The Collaborative Cross, begun in 2005 with a grant from the Ellison Medical Foundation, represents a fundamentally new way of conducting genetics research and aims to create 1,000 strains of mice that feature the genetic diversity of the world population. When completed in about five years, the research community will have access to an extremely versatile resource plus data that is the click of a mouse away. There will be other benefits as well.
“With our new facility at ORNL, we offer economies of scale for the production of populations of mice,” said Elissa Chesler, leader of the systems genetics group in the Biosciences Division. “Without having to maintain their own mouse colonies, researchers will have access to mice that will enable them to do experiments that cannot be done anywhere else.”
While conventional genetics studies have primarily involved stand-alone experiments aimed at discovering single gene variants, the Collaborative Cross represents the new approach that researchers say is necessary to develop a community resource for understanding the genetic and environmental complexity of human diseases. With this approach, using a reference population that allows for high genetic diversity and large sample size, researchers can more effectively examine combinations of genes responsible for diseases. This combination is what makes the Collaborative Cross special.
“We can stop blaming single genes for causing diseases,” Chesler said. “We now know that bad combinations of normal genes are at fault, and this mouse population will make it possible to determine complex causes and to develop drugs to treat those diseases.”
In one experiment at ORNL, William Lariviere of the University of Pittsburgh School of Medicine hopes to find genes that cause some people to be more sensitive to pain than others and to identify new drugs for treatment of different types of pain. The study involves collecting a standard set of thermal, chemical, inflammatory and mechanical sensitivity measures in groups of mice from 80 different lines in a genetic reference population called the BXD lines.
Data from Lariviere’s study will form an important foundation for integrative genomic analysis of pain. The results will be placed in the public domain through Web resource
http://www.genenetwork.org.
“The BXD lines are a powerful tool for integration, but they do not have maximum precision and genetic diversity,” Lariviere said. “For that, we will collect additional trait data in the Collaborative Cross mouse population being created at ORNL.”
One area of specific interest to Lariviere is variations in the amount of messenger RNA (mRNA) produced by different individuals. This often determines how much of a particular protein is made, and that in turn might be related to biological pathways that are involved in processes such as pain perception.
“Because we will measure both the mRNA levels and the sensitivity levels in the same strains of mice, we will be able to efficiently not only study the genes that cause individual differences in pain sensitivity, but also identify the pathway of genes that make ideal targets for new pain drugs,” Lariviere said.
In another study, Michael Miles of Virginia Commonwealth University leads a team that hopes to learn more about the connection between anxiety and alcoholism. Working with Alex Putman and Chesler, the researchers have identified a region of a mouse chromosome that appears to significantly alter the effects of alcohol on anxiety.
“Understanding the basic mechanisms connecting brain events in anxiety and alcoholism could lead to better treatments for both disorders,” Miles said.
In this study, researchers used special strains of mice being raised and maintained at ORNL. Miles noted that the strains of mice used for his study are not available through any commercial source and offer a “great advantage to genetic studies of complex diseases.”
In upcoming months the researchers hope to identify the actual genes in this chromosome region that alter the response to alcohol.
In another study, Bruce O’Hara of the University of Kentucky is working to identify sleep- and wake-related genes. In addition to gaining a more thorough understanding of the sleep process, this research could lead to better drugs to help people with sleep disorders.
O’Hara’s study takes advantage of noninvasive piezoelectric sensors instead of conventional techniques that use electroencephalogram and eletromyogram recordings, which require surgical implants and cables that tether the mouse to a recording device. This limitation has made it impractical to study large numbers of animals, which is necessary in genetic screening, according to O’Hara.
Source: Oak Ridge National Laboratory
Related stories:
Exercise pill is no replacement for exercise
Recently, researchers at the Salk Institute for Biological Studies, a research organization focused on biology and its relation to health,
published a study in the journal
Cell on the results of a substance that increased exercise endurance without daily exertion when tested in mice. Media reports have described this substance as an "exercise pill," potentially eliminating the need for exercise.
Relaxation response can influence expression of stress-related genes
How could a single, nonpharmacological intervention help patients deal with disorders ranging from high blood pressure, to pain syndromes, to infertility, to rheumatoid arthritis? That question may have been answered by a study finding that eliciting the relaxation response – a physiologic state of deep rest – influences the activation patterns of genes associated with the body's response to stress. The collaborative investigation by members of the Benson-Henry Institute for Mind/Body Medicine at Massachusetts General Hospital (MGH) and the Genomics Center at Beth Israel Deaconess Medical Center (BIDMC) appears in the open-access journal
PLoS One.
Pediatric researchers find possible 'master switch' gene in juvenile arthritis
Researchers have found that a gene region known to play a role in some varieties of adult rheumatoid arthritis is also present in all types of childhood arthritis. The researchers say the responsible gene may be a "master switch" that helps turn on the debilitating disease.
Complexity of Crohn's disease revealed as 'gene' count tops 30
New research has trebled the number of genetic regions known to be implicated in Crohn's disease, a form of inflammatory bowel disease, to over thirty. The research, published today in the journal
Nature Genetics, has identified a number of potential new targets for drug development as well as providing surprising new links between the condition and other common diseases including asthma.
Discovery of new family of genetic mutations involved in inflammatory intestinal disease
The discovery of new genetic mutations involved in inflammatory intestinal disorders could lead to a better understanding of these common conditions, two scientists told the annual conference of the European Society of Human Genetics today (Monday 2 June).
Platypus genome explains animal's peculiar features; holds clues to evolution of mammals
The duck-billed platypus: part bird, part reptile, part mammal -- and the genome to prove it. An international consortium of scientists, led by Washington University School of Medicine in St. Louis, has decoded the genome of the platypus, showing that the animal's peculiar mix of features is reflected in its DNA. An analysis of the genome, published today in the journal
Nature, can help scientists piece together a more complete picture of the evolution of all mammals, including humans.
Researchers look at cannabinoids, genes, medicines and brain scans to find better anxiety treatments
Right now, about half of all people who take medicine for an anxiety disorder don’t get much help from it. And doctors have no definitive way to predict who will, and who won’t, benefit from each anti-anxiety prescription they write.
Concentrating on different aspects of pain leads to breakthrough in migraine genetics
Migraine is the most common cause of episodic headache, and by far the most common neurological cause of a doctor’s visit. It affects some 15% of the population, including some 41 million people in Europe, and places a considerable burden on healthcare in both the developed and the developing world.